CHRS — Coherus Oncology Income Statement
0.000.00%
Last trade - 00:00- $248.82m
- $127.77m
- $42.17m
Annual income statement for Coherus Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 327 | 211 | 257 | 26.4 | 42.2 |
| Cost of Revenue | |||||
| Gross Profit | 269 | 141 | 98.3 | 17.7 | 28.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 590 | 474 | 460 | 239 | 223 |
| Operating Profit | -264 | -263 | -203 | -212 | -181 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -287 | -292 | -238 | -215 | -183 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -287 | -292 | -238 | -215 | -183 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -287 | -292 | -238 | 28.5 | 168 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -287 | -292 | -238 | 28.5 | 168 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.81 | -3.68 | -2.46 | -1.65 | -1.49 |